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Abstract
To determine the frequency, risk factors and mortality of nosocomial pneumonia a prospective 
study was conducted in the intensive care units. In the study period, 2402 patients were included. 
The nosocomial pneumonia was defined according to  the Centers for Disease Control Criteria. 
Overall, 163 (6.8%) of the patients developed nosocomial pneumonia and 75.5% (n = 123) of all 
patients with nosocomial pneumonia were ventilator-associated pneumonia. I6 3  patients who 
were admitted to the intensive care unit during the same period but had no bacteriologic or 
histologic evidence of pneumonia were used as a control group. The APACHE II score, coma, 
hypoalbuminemia, mechanical ventilation, tracheotomy, presence of nasogastric tube were found 
as independent risk factors. Crude and attributable mortality were 65% and 52.6%, respectively. 
The mortality rate was five times greater in the cases (OR: 5.2; CI 95%: 3.2-8.3). The mean length 
of stay in the intensive care unit and hospital in the cases were longer than controls (p < 0.0001). 
Patients requiring mechanical ventilation have a high frequency of nosocomial pneumonia.
Background
Nosocomial pneum onia (NP) is the most frequent noso­
comial infection in the intensive care units (ICU). The 
reported frequency varies with the definition, the type of 
hospital or ICU, the population of patients, and the type 
of rate calculated. In the recent studies, the incidence was 
reported as 6.8-27% [1-4]. In an one day point prevalence 
study in European ICUs, ICU-acquired pneumonia 
accounted for 46.9% of nosocomial infections [5]. The 
National Nosocomial Infections Surveillance (NNIS) sys­
tem reported that NP accounts for 31% of all nosocomial
infections in intensive care units [6]. The risk of pneum o­
nia is increased in the intubated patients receiving 
mechanical ventilation (MV) and the ventilator associated 
pneum onia (VAP) frequencies varied between 7-70%  in 
different studies [7-9]. NP developed at a rate of 0.9 cases 
per 1000 patient-days in non-ventilated patients versus 
rates of 20.6 cases per 1000 patient-ventilator-days and
14.8 cases per 1000 patient-days in patients who received 
any MV [10]. NP is also associated with high morbidity 
and mortality in ICUs. The increasing incidence of infec­
tions caused by antibiotic-resistant pathogens contributes
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to the seriousness of these infections. The mortality rate 
reaches to 20-50% , and also NP caused by high-risk path­
ogens (Pseudomonas aeruginosa, Acinetobacter spp., Stenotro- 
phomonas maltophilia) are associated with higher mortality 
[1,11,12]. Patients with NP, stay 1 to 2 weeks longer than 
those without NP and result in higher costs [13].
Studies on NP are mainly reported from the United States 
and European countries, whereas studies from around the 
world are missing. The aims of this study were to assess 
incidence, risk factors and mortality of NP in Eurasian 
intensive care units.
Methods
Between February 2001 and February 2002 a prospective 
study was conducted among intensive care units (ICU) 
patients of the Erciyes University Hospital. This university 
hospital is a teaching hospital and full time intensivists 
care the patients in ICUs. Patients from the surgical ICU 
(SICU) (24 beds), medical ICU (MICU) (9 beds) and 
burn unit (7 beds) were included. The SICU consist of 8 
neurosurgical (NICU), 8 general surgery (GICU) and 8 
cardiac surgery (CICU) beds. Patients older than 16 yr of 
age were included. The same infection control doctor col­
lected data and intensivist reviewed the diagnosis of pneu­
monia. Data collection included physical examination 
findings, APACHE II scores on admission, consciousness, 
risk factors (intubation, MV, presence of nasogastric tube, 
enteral nutrition, tracheotomy), prior surgery, im m uno­
suppression, prior antimicrobial and antacid or histamine 
type 2 (H2) blocker therapy, clinical outcome, length of 
stay in ICU and in the hospital.
163 patients who were admitted to the ICU during the 
same period but had no bacteriologic or histologic evi­
dence of pneum onia were used as a control group.
In the ICUs infection control doctor collects active surveil­
lance data routinely and empiric antibiotic therapy is 
directed at the most prevalent and virulent pathogens 
reported in these data. Appropriate antibiotic therapy 
included the administration of at least one antibiotic with 
in vitro activity against the bacterial pathogens isolated 
from the patient's respiratory secretions, as well as from 
blood and pleural fluid when applicable [14].
NP was considered when new and persistent (more than 
48 h) pulmonary infiltrates not otherwise explained 
appeared on chest radiographs. Moreover, at least two of 
the following criteria were also required: 1) fever >38°C; 
2) peripheral leukocyte count >10 000/m m 3; 3) purulent 
endotracheal secretions with a Gram stain showing one or 
more types of bacteria [15]. VAP was considered when its 
onset occurred after 48 h of MV and was judged no t to 
have been incubated before starting MV [16]. Admission
APACHE II score was used to determine the severity of the 
illness, and attributable mortality was registered, as were 
laboratory values, electrocardiogram, x-ray, and arterial 
blood gas values.
Extra length of stay was calculated comparing the extra 
stay after onset of pneum onia in the cases and after a ref­
erence date (the mean value of the extra stay after onset of 
pneum onia in the cases) in the control group.
M icrobiology
Giemsa stains of sputum samples were performed for all 
patients. Sputum samples, containing more than 25 poli- 
morphonuclear leukocyte (pnl) and less than 10 (x100) 
epithel were classified as purulent. If necessary, samples 
were obtained by nasotracheal aspiration. In that case, 
samples containing more than 10 pnl (x1000) were 
defined as purulent. Quantitative cultures of all purulent 
samples were performed using standard methods. Suscep­
tibility testing was performed by disc diffusion method. In 
the absence of an alternative diagnosis a bronchoalveolar 
lavage was performed. In some case, pleural fluid was 
obtained by thoracentesis and examined for cell count, 
smear, Gram- and Giemsa-staining and microbiological 
culture.
Statistical Analysis
All data were evaluated using SPSS. Parameters were com­
pared using univariate and multivariate logistic regression 
and chi-square tests. Student t test was used to compare 
the extra length of stay. Data were given as mean ± SD and 
a p-value of <0.05 was accepted as significant.
Results
During the study period, 2402 patients were admitted to 
the ICUs. Distribution of patients by ICU and length of 
stay in the ICU are shown in table 1. Overall, 163 (6.8%) 
ofthe 2402 patients developed NP; 105 (5.8%) SICU- and 
58 (11.7%) MICU-patients. The demographics of the NP 
patients and control group are shown in table 2. The per­
centage of NP in NICU, GICU and CICU were 7.8%, 6.3% 
and 1.2%, respectively. During the study period no burn 
unit patient developed NP. The incidence of NP in MICU- 
patients was much higher than in SICU-patients (X2 = 
19.7, p < 0.0001). Length of stay in the MICU was signif­
icantly higher than in the SICU, 21.3 ± 21.4 versus 16.2 ±
8.8 days, respectively (p < 0.05). Characteristics of 
patients who developed NP are shown in table 3.
Overall, 17% of all patients requiring MV (n-724) devel­
oped VAP. Thereby, VAP accounts for 75.5% (n = 123) of 
all patients with NP (n = 163) during the study period 
(OR: 5,4; 95% CI: 3,36-8,75; p < 0,001) (Table 4). 
Mechanical ventilation was more frequently used in 
MICU patients than SICU patients (X2 = 6.6, p < 0.01).
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Tab le  I: N um bers o f patients and length o f stay in IC U
IC U N o . o f  beds T o ta l p a tie n t (n ) T o ta l length o f stay (d ) M ean length o f stay (d )
S IC U 24 1806 5594 3.1
NICU 8 767 2213 2.9
GICU 8 636 2132 3.4
CICU 8 403 1249 3.1
M IC U 9 495 2086 4.2
B urn U n it 7 111 1765 15.9
T o ta l 40 2402 9445 3.9
Tab le  II: D em ographic Factors o f S tudy P atients*
N P  patien ts  (n =  163) C o n tro l (n  =  163) t p
A g e 53.30 ± 16.05 5 I.50  ± I6 .8 7 0,985 >0,05
A dm ission A P A C H E  II I0 .8 6  ± 3.42 I0 . I8  ± 4.56 I,526 >0,05
G e n d e r 0,454 >0,05
M ale 98 (60) I0 2  (63)
F e m a le 65 (40) 61 (37)
D iab e te s  m ellitus 22 (I4 ) 32 (20) 1,49 >0,05
C O P D 36 (22) I I  (7) 4,027 <0.001
C ard io vascular disease 31 (19) 19 (12) I,848 >0,05
U re m ia 36 (22) I2  (7) 3,823 <0.001
N eo plas ia 29 (I8 ) 17 (10) 1,914 >0,05
Im m unosuppressive th erap y 6 (4) 3 (2) 1,013 >0,05
C o m a I4 3  (88) 23 (14) I9,58 <0,001
T ra u m a 35 (22) 85 (52) 6,038 <0,001
*  Data presented as mean ± SD o r  No. (%)
Tab le  III: C haracteristics o f patients
C haracteris tics M IC U N IC U G IC U C IC U T o ta l
Age (mean ± SD)
Admission APACHE II, (mean ± SD) 
NP APACHEII, (mean ± SD)
Length o f stay in ICU (d, mean ± SD) 
Length o f hosp. stay (d, mean ± SD)
52.9 ± 15.1
11.2 ± 3.3
16.2 ± 5.1
21.3 ± 21.4 
25.0 ± 22.5
50.25 ± 17.57 
10.43 ± 3.12 
14.73 ± 3.94 
14.42 ± 8.87 
21.60 ± 11.93
58.28 ± 14.38 
11.03 ± 3.67 
16.30 ± 4.79 
19.47 ± 8.20 
24.78 ± 12.13
55.00 ± 14.68 
1 1.20 ± 6.38 
14.80 ± 6.37 
12.20 ± 3.96 
18.40 ± 8.26
53.3 ± 16.1 
10.9 ± 3.4 
15.6 ± 4.7 
18.0 ± 14.7 
23.5 ± 16.4
Tab le  IV: R ate o f V A P  in IC U s
IC U N o . o f  pa tien ts req u ire d  M V N o . o f  pa tien ts  w ith  V A P  (%)
SICU 550 72 (13.1)
N IC U I4 I 38 (27.0)
GICU 157 31 (19.7)
CICU 252 3 (1.2)
MICU I63 51 (31.3)
Burn un it I I 0 (0)
T o ta l 724 123 (1 7 .0 )
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Consequently, the incidence of VAP was higher for MICU- 
than SICU-patients (X2 = 29.2, p < 0.0001). Furthermore, 
the length of ventilation was higher for patients admitted 
to MICU (6.3 ± 4.0) than SICU (5.1 ± 3.7), but the differ­
ence was not statistically significant.
During the study period patients received 3128 ventila­
tion days, with an average duration of 11.3 ± 10.0 days per 
ventilated patient. The device-related incidence rate for 
VAP was 39.3/1000 ventilation days. The incidence per 
1000 ventilation days was 41.9 in SICU, 36.6 in MICU, 
66.0 in NICU, 38.0 in GICU, and 9.1 in CICU patients. 
The mean onset day of NP after MV was 4.2 ± 3.9 days.
Univariate analysis suggested the following risk factors for 
the development of NP: the APACHE II score, coma, 
COPD, uremia, hypoalbuminemia, MV, tracheotomy, 
enteral feeding, presence of nasogastric tube and previous 
treatment with broad-spectrum antibiotic (Table 5). How­
ever, multivariate logistic regression showed that the 
APACHE II score (OR: 1.23; 95% CI: 1.13-1.33), coma 
(OR: 2.83; 95% CI: 1.24-6.47), hypoalbuminemia (OR: 
2.23; 95% CI: 1.01-4.93), MV (OR: 3.35; 95% CI: 1.71­
6.56), tracheotomy (OR: 6.03; 95% CI: 1.36-26.76) and 
presence of nasogastric tube (OR: 2.68; 95% CI: 1.33­
5.41) were significant independent predictive factors for 
the development of NP.
187 pneum onia episodes were observed during the study 
period, resulting in the isolation of 257 microorganisms. 
The most commonly isolated pathogens were Gram-neg­
ative bacteria (85.6%). Among these pathogens, A. bau- 
mannii (29.6%), P. aeruginosa (20.6%), Klebsiella 
pneumoniae (14.4%) were the most common.
Empiric antibiotic therapy was based on previous surveil­
lance cultures and the Gram stain results. Therapy was 
adjusted according to the reports of susceptibility testing.
Crude and attributable mortality were 65% and 52.6%, 
respectively. The mortality in patients without NP was 
26.4% (Table 6). The risk of death was five times higher 
for patients with NP (OR: 5.2; 95% CI: 3.2-8.3; p < 
0,001). The mortality rates were high in high risk patho­
gens (Table 7). The appropriateness of the empiric therapy 
did not contribute to increased mortality (Table 8).
The mean length of stay in the ICU and hospital for the 
patients with NP were 18.04 ± 14.74 days and 23.49 ± 
16.44 days, respectively. The mean length of stay in the 
ICU and hospital for the control group 3.10 ± 3.03 and 
9.64 ± 5.08 days, respectively. This difference was statisti­
cally significant (p < 0.0001). The extra stay in the control 
group was 4.36 ± 3.87 and 17.04 ± 14.17 in the patients 
(p < 0.001).
Discussion
The incidence of NP was reported different in different 
studies, which may be justified by the presence of differ­
ent populations with variable ages, underlying diseases, 
and other associated risk factors. Incidence ranges from
6.8 to 27% [1-4] and also in this study it was 6.8%. Devel­
opm ent of NP varies according to the different type of 
ICUs. Craven et al. [17] reported that the rate of pneum o­
nia was higher in MICU but the difference was not signif­
icant. In the present study, the rate of NP and VAP was 
significantly higher in MICU than SICU, possible due to 
the differences in the proportion of patients that needed 
MV and the duration of MV.
MV increases the risk of NP by 3- to 10-fold [1,18-23], 
resulting in an VAP incidence of 7 to 70% [7-9]. Gener­
ally, the duration of mechanical ventilation increases the 
risk of pneumonia. Cook et al. [24] reported that the rate 
of VAP increased 3% per day in the first week of 
ventilation, 2% per day in the second week, and 1% per 
day in the third week. In this study, 75.5% of the cases 
with NP occurred in ventilated patients. From 724 
patients who required MV 123 (17%) developed VAP. 
Accordingly, patients on MV had a 3-fold higher risk to 
develop NP than the non-ventilated patients. 
Consequently, the use of non-invasive MV should be pre­
ferred whenever possible, since it has lower rates of noso­
comial infections [25-27].
Coma was described as another important risk factor for 
NP. In these patients, local defense mechanisms of the res­
piratory airway are altered, allowing microorganisms to 
better attach to and colonize the mucosal surface. Further­
more, depression of the level of consciousness signifi­
cantly increases the chance of aspiration, and as a result 
development of NP [3,28]. In our study, comatose 
patients had a 2-fold increased risk of NP.
The causative agents of NP differ by the study population 
and diagnostic techniques but generally Gram-negative 
bacteria are the most common ones [3,4,28-33]. Coloni­
zation of the oropharynx, trachea or stomach with Gram­
negative pathogens has been identified as a risk factor for 
NP [15,31]. Also in our study, the most common patho­
gens were Gram-negative bacteria. Furthermore, prior 
antibiotic therapy and COPD, leading to colonization 
with Gram-negative aerobic pathogens, were reported to 
be risk factors for the development of NP [11,28,30,34]. 
In our patient population, univariate analysis suggested 
that previous antibiotic treatment and COPD increased 
the risk of pneumonia, but interestingly they were not 
independent risk factors in multivariate analysis. Further­
more, the presence of a naso-gastric tube was found to be 
a risk factor in our study population. Naso-gastric tubes 
impair the function of the gastroesophageal sphincter and
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Tab le  V: Results o f un ivaria te  analysis o f p otentia l risk factors fo r N P
Risk Factors O R 95% C onfidence In terva l p
Age 1.0 0.99 -  1.02 ns
APACHE II 1.3 1.22 -  1.38 <0.001
Coma 6.6 3.75 -  11.48 <0.001
Trauma 1.7 0.93 -  2.97 ns
COPD 3.9 1.91 -  8.01 <0.001
Diabetes mellitus 0.6 0.35 -  1.16 ns
Centra l nervous system disorder I.I 0.71 -  1.77 ns
Urem ia 3.6 1.78-7.14 <0.001
Hypoalbuminemia 3.3 1.99-5.61 <0.001
Mechanical ventila tion 5.4 3.36-8.75 <0.001
Tracheotom y 12.5 3.75-41.89 <0.001
Enteral feeding 13.9 6.38-30.13 <0.001
Presence o f nasogastric 6.3 3.89-10.18 <0.001
Previous an tibiotic treatm ent 3.3 1.94-5.62 <0.001
Immunosupressive therapy 2.0 0.50-8.29 ns
Antacids o r  H2 antagonist therapy 0.6 0.25-1.36 ns
Thoracoabdominal surgery 1.0 0.63-1.69 ns
ns: non-significant
Tab le  V I: Com parisons o f outcom es betw een N P  and contro l group
N P  group n (%) C o n tro l grou p  n (%) X 2 p
M orta lity
Improve
A ttribu tab le  m orta lity
106 (65.0) 
57 (35.0)
52.6%
43 (26.4) 
120 (73.6)
47.5 <0.0001
Tab le  V II: M o rta lity  rates in high risk pathogens
M icro organ ism M o rta lity /T o ta l (%)
G ra m  negative 61 /97  (6 2 .9 )
A. baumannii 31/42 (73.8)
P. aeruginosa 19/28 (67.9)
G ra m  positive 10/15 (6 6 .7 )
MRSA 10/14 (71.4)
Tab le  V III:  A ppropriateness o f em piric  th erapy and m o rta lity
A p p ro p r ia te  n (%) In a p p ro p ria te  n (%) X 2 p
S urvive  43/121 (35.5) 
D e a th  78/121 (64.5)
14/42 (33.3) 
28/42 (66.7)
0.005 >0.05
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increase the risk of maxillary sinusitis, oropharyngeal col­
onization and reflux, all of which may lead to migration 
of bacteria [35]. Accurate evaluation of nutritional status 
and early initiation of enteral feeding is im portant in ICUs 
patients and can aid to preserve the gastrointestinal epi­
thelium and prevent bacterial colonization. However, it 
may also increase the risk of gastric distention, coloniza­
tion, aspiration, and pneumonia. Though, to reduce the 
risk of NP, it is important to avoid unnecessary enteral 
nutrition [30]. In univariate analysis, we found enteral 
feeding as a risk factor, but in multivariate analysis it was 
not an independent risk factor. For a long time it was 
assumed that increased gastric pH levels e.g. after the use 
of antacids, would allow Gram-negative microorganisms 
to multiply in the stomach, and consequently lead to an 
increased rate of NP. Our study results confirm what was 
reported by George et al. [36], namely that the use antac­
ids or H2 antagonists did no t increase the risk of NP.
In the literature, tracheotomy is described as a significant 
risk factor for NP. Bronchial colonization during the pro­
cedure and (prolonged) continuation of sedation after the 
procedure will furthermore increase the occurrence of NP 
[28], a fact that was also seen in our patients. Patients with 
tracheotomy had a 7-fold increased risk of NP.
The role of advanced age and high APACHE II scores as 
risk factors of NP are still under discussion. While Kollef 
et al. [37] report them as significant risk factors, earlier 
investigations do not support this [1,30]. In our present 
study, the APACHE II score was a significant risk factor for 
the development of NP; suggested that the severity of the 
general condition of the patient was important. Besides, 
uremia was found as a risk factor in univariate analysis.
Patients with NP have a significantly higher morbidity 
and mortality [12,35,38]. Heyland et al. [38] reported the 
crude mortality rate of VAP 23.7% and an attributable 
mortality rate 32.3%. However, numerous studies have 
demonstrated that severe underlying illness predisposes 
patients in the ICU to the development of pneumonia, 
and their mortality rates are, as a result, high. Survival in 
patients with NP primarily by the degree of severity of ill­
ness at the time of diagnosis [23,39,40]. On the other 
hand, this does not exclude the possibility that certain 
subgroups of patients, such as patients with VAP caused 
by antibiotic resistant bacteria may have had extra attrib­
utable mortality rate [1]. In our study, the crude mortality 
rates for cases and controls were 65.0% and 26.4%, 
respectively and the mortality rates were highest in high 
risk pathogens. The mortality rate was five times greater in 
cases and attributable mortality of NP was 52.6%. Recent 
clinical investigations suggest that patients receiving inap­
propriate initial therapy have a greater mortality rate com­
pared to patients receiving antibiotics to which the
isolated bacteria were sensitive. However, in this study 
there was no statistically difference between the mortality 
rates of the patients who received appropriate and inap­
propriate initial therapy.
As a result of the increased morbidity, patients with VAP 
remain hospitalized for 4-17  days longer than controls 
[35-38]. This observation was confirmed in the present 
study. The incidence of NP and VAP in MICU were signif­
icantly higher than in SICU patients and consequently the 
length of stay in the MICU was significantly higher than 
in the SICU.
In conclusion, NP is a major cause of morbidity and m or­
tality in ICU patients. Especially patients on mechanical 
ventilation are at high risk. Studies determining the 
impact of "old" and "new" risk factors of NP should 
repeatedly be performed in order to effectively guide the 
implementation of preventive measures methods.
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